Back to all papers

Choroid plexus enlargement in unmedicated major depressive disorder inflammation, oxidative stress and treatment outcome.

November 18, 2026pubmed logopapers

Authors

Jensen KHR,Alakhir S,Köhler-Forsberg K,Falk K,Pernet C,Frokjaer VG,Jørgensen MB,Jørgensen A

Affiliations (4)

  • Neurobiology Research Unit, Rigshospitalet, Copenhagen, Denmark; Psychiatric Center Copenhagen, Bispebjerg-Frederiksberg Hospital, Copenhagen, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark. Electronic address: [email protected].
  • Neurobiology Research Unit, Rigshospitalet, Copenhagen, Denmark; Psychiatric Center Copenhagen, Bispebjerg-Frederiksberg Hospital, Copenhagen, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
  • Neurobiology Research Unit, Rigshospitalet, Copenhagen, Denmark.
  • Psychiatric Center Copenhagen, Bispebjerg-Frederiksberg Hospital, Copenhagen, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.

Abstract

The choroid plexus has emerged as a putative neuroimmune interface implicated in major depressive disorder (MDD). Choroid plexus enlargement has been reported across several MDD cohorts, yet its relationship with peripheral inflammation, oxidative stress, and antidepressant treatment response remains unresolved. We used data from NeuroPharm-1, an open-label trial of escitalopram in 96 unmedicated patients with moderate-to-severe MDD and 84 healthy controls (HC) aged 18 to 57 years. Choroid plexus volume (CPV) was measured using deep-learning-based segmentation of T1-weighted MRI. Peripheral inflammation was indexed by high-sensitivity C-Reactive Protein (hsCRP), and oxidative stress by urinary 8-oxodG and 8-oxoGuo. Group differences in CPV were examined using a general linear model controlling for age, sex, BMI, and total intracranial volume. Associations with inflammation, oxidative stress, and treatment effects over 12 weeks were assessed in secondary and exploratory analyses. Analyses were preregistered at AsPredicted.org (ID 270379) RESULTS: Patients showed larger CPV than HC (β = 194 mm3 [9, 378], p = 0.040; Hedges' g = 0.32). However, pretreatment CPV was not associated with depression severity (HAMD17), hsCRP, or oxidative stress. Pretreatment CPV did not predict symptom trajectory over 12 weeks. CPV remained stable from baseline to week 8, with no significant change (p = 0.452). This study replicates CPV enlargement in unmedicated MDD, strengthening evidence that it is a feature of the disorder. CPV was unrelated to peripheral inflammatory and oxidative stress markers, suggesting cumulative blood-CSF barrier reactivity rather than concurrent circulating inflammation. CPV did not decrease with treatment, suggesting high short-term stability.

Topics

Journal Article

Ready to Sharpen Your Edge?

Subscribe to join 11k+ peers who rely on RadAISlice. Get the essential weekly briefing that empowers you to navigate the future of radiology.

We respect your privacy. Unsubscribe at any time.